In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Abbott Vascular

Division of Abbott Laboratories Inc.
www.abbottvascular.com

Latest From Abbott Vascular

TCT 2018: New ABSORB Trial Data Fails To Impress

Abbott's defunct Absorb BVS stent's efficacy is noninferior to that of the Xience metallic everolimus-eluting stent, new data presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference in San Diego show. But the risk of thrombotic events was still higher with Absorb. This prompted a discussion among panelists whether bioresorbable stents should still be investigated, given the availability of newer-generation drug-eluting stents, which have shown to be safer.

Clinical Trials Research & Development

TCT 2018: Abbott Expects COAPT Results To Support Expanding MitraClip's Indication

Data presented at the Transcatheter Cardiovascular Therapeutics conference Sept. 23 in San Diego will support expanding the label of Abbott's MitraClip mitral valve repair device to include secondary, or functional, mitral regurgitation, a company executive tells Medtech Insight. In the COAPT trial, MitraClip reduced the two-year rate of heart-failure hospitalization and all-cause mortality in patients with heart failure and moderate-to-severe or severe secondary mitral regurgitation.

Clinical Trials Innovation

ESC Congress 2018 Wrap-Up: Medtronic's Arctic Front; B. Braun's SeQuent Please; Biotronik's Orsiro Stent

Almost 33,000 cardiology professionals attended the 2018 European Society of Cardiology Congress last week in Munich. The meeting included 4,500 abstracts, including 17 late-breaking clinical trials, six clinical trial updates, and 20 registries. Here are some of the highlights of interest to the medtech industry.

Clinical Trials Research & Development

ESC Congress 2018: MITRA-FR Finds No Benefit Of MitraClip In Severe Secondary MR

Patients with severe secondary mitral regurgitation treated with MitraClip and medical therapy have the same rate of death or unplanned hospitalization for heart failure at one year as patients treated with medical therapy alone, results of MITRA-FR show. Abbott, as well as other companies developing transcatheter mitral-repair technology, will now look to the COAPT trial to establish MitraClip's benefits on clinical outcomes.

Clinical Trials Research & Development
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Cardiovascular
  • Alias(es)
  • Abbott Vascular Devices
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Abbott Laboratories Inc.
  • Senior Management
  • Contact Info
  • Abbott Vascular
    Phone: (408) 845-3000
    3200 Lakeside Dr.
    Santa Clara, CA 95054-2807
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register